@FierceBiotech: Roche readies for approvals of previously snubbed breast cancer drug T-DM1. More | Follow @FierceBiotech
@JohnCFierce: Oracle acquires ClearTrial--the "cloud" for clinical trial data. More | Follow @JohnCFierce
@RyanMFierce: Isis is due $25M if the FDA accepts newly submitted NDA for mipomersen. Article | Follow @RyanMFierce
> Sunesis Pharmaceuticals has landed a deal with Royalty Pharma that could bring $25 million under certain terms in exchange for giving Royalty royalties on potential future sales of its lead drug vosaroxin, which is in Phase III trials as a treatment for acute myeloid leukemia. Release
> Shire ($SHPGY) plans to conduct studies to support the benefit of the drug midodrine after U.S. regulators snubbed Chelsea Therapeutics ($CHTP) in its bid to get approval for a potential rival therapy known as Northera. Report
> Sanofi ($SNY) and Isis Pharmaceuticals ($ISIS) have submitted an application for FDA approval of their drug mipomersen for homozygous familial hypercholesterolaemia (HoFH), and Isis is due a $25 million fee if U.S. regulators accept the application for review. Item
> Shares of Threshold Pharmaceuticals ($THLD) got a boost after the South San Francisco-based drug developer reported that the FDA has granted orphan status for its experimental treatment TH-302 for combating rare cancer called soft tissue sarcoma. Article
> U.S. biotech NGM Biopharmaceuticals has scored a partnership with Japan's Daiichi Sankyo to research new drugs for diabetes. Financial terms were not disclosed. Report
Pharma News
@FiercePharma: France's drug market to shrink this year. No surprise, given the austerity-related cost cuts. Article | Follow @FiercePharma
> Dendreon's Provenge faces new questions. More
> Bayer gets positive ruling from NICE on Xarelto. News
> North Carolina considers drug liability protections. Story
> France's drug spending will shrink for first time, IMS says. Article
Medical Device News
@FierceMedDev: Europe Weighs Tougher Breast Implant Scrutiny - BusinessWeek. Story | Follow @FierceMedDev
> After 11 malfunctions, St. Jude pulls Brio DBS device. News
> FDA panel to hear experts, patients on metal hips. Story
> Globus files for estimated $100M IPO. Article
> Roche pressures Illumina with higher, $6.7B offer. More
And Finally… Finally, Roche ($RHHBY) has upped its bid to acquire DNA sequencing machine maker Illumina ($ILMN). Details